JP2008500009A5 - - Google Patents

Download PDF

Info

Publication number
JP2008500009A5
JP2008500009A5 JP2006532309A JP2006532309A JP2008500009A5 JP 2008500009 A5 JP2008500009 A5 JP 2008500009A5 JP 2006532309 A JP2006532309 A JP 2006532309A JP 2006532309 A JP2006532309 A JP 2006532309A JP 2008500009 A5 JP2008500009 A5 JP 2008500009A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006532309A
Other languages
Japanese (ja)
Other versions
JP2008500009A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/006460 external-priority patent/WO2005051988A2/en
Publication of JP2008500009A publication Critical patent/JP2008500009A/ja
Publication of JP2008500009A5 publication Critical patent/JP2008500009A5/ja
Pending legal-status Critical Current

Links

JP2006532309A 2003-03-03 2004-03-02 全身性エリテマトーデスの治療のための組成物と方法 Pending JP2008500009A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45188403P 2003-03-03 2003-03-03
PCT/US2004/006460 WO2005051988A2 (en) 2003-03-03 2004-03-02 Compositions and methods for the treatment of systemic lupus erythematosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010089887A Division JP2010207229A (ja) 2003-03-03 2010-04-08 全身性エリテマトーデスの治療のための組成物と方法

Publications (2)

Publication Number Publication Date
JP2008500009A JP2008500009A (ja) 2008-01-10
JP2008500009A5 true JP2008500009A5 (cg-RX-API-DMAC7.html) 2009-05-14

Family

ID=34632721

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006532309A Pending JP2008500009A (ja) 2003-03-03 2004-03-02 全身性エリテマトーデスの治療のための組成物と方法
JP2010089887A Pending JP2010207229A (ja) 2003-03-03 2010-04-08 全身性エリテマトーデスの治療のための組成物と方法
JP2013121971A Pending JP2013240329A (ja) 2003-03-03 2013-06-10 全身性エリテマトーデスの治療のための組成物と方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010089887A Pending JP2010207229A (ja) 2003-03-03 2010-04-08 全身性エリテマトーデスの治療のための組成物と方法
JP2013121971A Pending JP2013240329A (ja) 2003-03-03 2013-06-10 全身性エリテマトーデスの治療のための組成物と方法

Country Status (6)

Country Link
US (2) US7749695B2 (cg-RX-API-DMAC7.html)
EP (1) EP1599498A2 (cg-RX-API-DMAC7.html)
JP (3) JP2008500009A (cg-RX-API-DMAC7.html)
AU (2) AU2004293369A1 (cg-RX-API-DMAC7.html)
CA (1) CA2518101A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005051988A2 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020042062A1 (en) * 1999-09-24 2002-04-11 Mark Stearns Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
US7790861B2 (en) * 1999-09-24 2010-09-07 Philadelphia Health And Education Corporation Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
US7754435B2 (en) * 2000-09-21 2010-07-13 Philadelphia Health And Education Corporation Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
WO2007043103A1 (ja) * 2005-09-30 2007-04-19 Kansai Technology Licensing Organization Co., Ltd. シェーグレン症候群診断法及び診断キット
CN101473045B (zh) 2006-04-24 2016-08-03 健泰科生物技术公司 用于检测自身免疫性病症的方法和组合物
US20100104581A1 (en) * 2006-05-25 2010-04-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for Diagnosing and Treating Graft Rejection and Inflammatory Conditions
EP1905841A1 (en) * 2006-09-25 2008-04-02 Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; Trex1 as a marker for lupus erythematosus
WO2010011965A2 (en) * 2008-07-24 2010-01-28 The Regents Of The University Of California Identifying high risk clinically isolated syndrome patients
SMT201700063T1 (it) * 2009-09-03 2017-03-08 Medimmune Llc Diagnosi di interferoni di tipo 1
EP2621514B1 (en) 2010-09-28 2016-09-21 KAHR Medical (2005) Ltd Compositions and methods for treatment of hematological malignancies
DK2831109T3 (en) 2012-03-28 2018-02-12 Gadeta B V COMBINATORY GAMMA-9-DELTA-2-T-CELL RECEPTOR CHAIN EXCHANGE
ES2987986T3 (es) 2016-06-10 2024-11-18 Gadeta B V Nuevo método para identificar cadenas de receptores de células T delta (o células T gamma) o partes de estas que intervienen en una respuesta antitumoral o antiinfecciosa
EP3541407A1 (en) * 2016-11-18 2019-09-25 Universitat de Barcelona Combined cd6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル-マイヤーズ スクイブ カンパニー アルファ-シヌクレインに対する抗体およびその使用
BR112020013845A2 (pt) * 2018-01-09 2020-12-01 Imagine Pharma, Llc polipeptídeo ou formulação, métodos para modulação de crescimento celular endotelial e para tratamento de uma doença, e, uso de um polipeptídeo ou formulação.
GB202012804D0 (en) 2020-08-17 2020-09-30 Univ London Queen Mary Agrin polypeptide and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016660A1 (en) * 1991-03-22 1992-10-01 Sloan-Kettering Institute For Cancer Research Methods for detection and treatment of cancer
WO2000015797A2 (en) * 1998-09-17 2000-03-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2001040465A2 (en) * 1999-11-30 2001-06-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
KR20010103046A (ko) * 1999-03-08 2001-11-17 제넨테크, 인크. 면역 관련 질환 치료용 조성물 및 치료 방법
JP2002543764A (ja) * 1999-03-19 2002-12-24 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 46個のヒト分泌タンパク質
ES2333772T3 (es) * 1999-12-23 2010-03-01 Genentech, Inc. Polipeptidos homologos de il-17 y il-17r y sus utilizaciones terapeuticas.
AU2001234944A1 (en) * 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
CA2402525A1 (en) 2000-03-31 2001-10-11 Genentech, Inc. Compositions and methods for detecting and quantifying gene expression
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001274888A1 (en) * 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001294943A1 (en) * 2000-10-02 2002-04-15 Bayer Corporation Nucleic acid sequences differentially expressed in cancer tissue
US20020137081A1 (en) * 2001-01-08 2002-09-26 Olga Bandman Genes differentially expressed in vascular tissue activation
EP1409677A2 (en) 2001-01-19 2004-04-21 Incyte Genomics, Inc. Receptors and membrane-associated proteins
WO2003010327A2 (en) * 2001-02-21 2003-02-06 Curagen Corporation Novel proteins and nucleic acids encoding same
AU2002324700A1 (en) * 2001-08-14 2003-03-03 Bayer Ag Nucleic acid and amino acid sequences involved in pain
US6489153B1 (en) * 2001-10-31 2002-12-03 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
US20040258678A1 (en) * 2002-02-22 2004-12-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2004121218A (ja) * 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
US7118865B2 (en) * 2002-08-16 2006-10-10 Regents Of The University Of Minnesota Methods for diagnosing severe systemic lupus erythematosus
JP2006521082A (ja) 2002-09-11 2006-09-21 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
WO2004028479A2 (en) * 2002-09-25 2004-04-08 Genentech, Inc. Nouvelles compositions et methodes de traitement du psoriasis
CA2500687A1 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1578368A4 (en) * 2002-11-12 2008-01-23 Genentech Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
EP1572116A4 (en) * 2002-11-26 2007-12-12 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
WO2004076639A2 (en) * 2003-02-26 2004-09-10 Wyeth Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus

Similar Documents

Publication Publication Date Title
BE2024C508I2 (cg-RX-API-DMAC7.html)
BE2022C549I2 (cg-RX-API-DMAC7.html)
BE2020C517I2 (cg-RX-API-DMAC7.html)
BE2019C540I2 (cg-RX-API-DMAC7.html)
BE2019C523I2 (cg-RX-API-DMAC7.html)
BE2019C548I2 (cg-RX-API-DMAC7.html)
BE2019C506I2 (cg-RX-API-DMAC7.html)
BE2020C525I2 (cg-RX-API-DMAC7.html)
BE2017C027I2 (cg-RX-API-DMAC7.html)
BE2017C023I2 (cg-RX-API-DMAC7.html)
BE2017C002I2 (cg-RX-API-DMAC7.html)
BE2016C014I2 (cg-RX-API-DMAC7.html)
BE2016C020I2 (cg-RX-API-DMAC7.html)
BE2015C041I2 (cg-RX-API-DMAC7.html)
BE2015C038I2 (cg-RX-API-DMAC7.html)
BE2015C014I2 (cg-RX-API-DMAC7.html)
BE2014C064I2 (cg-RX-API-DMAC7.html)
BE2014C010I2 (cg-RX-API-DMAC7.html)
BE2013C071I2 (cg-RX-API-DMAC7.html)
BE2013C021I2 (cg-RX-API-DMAC7.html)
BE2015C066I2 (cg-RX-API-DMAC7.html)
JP2005084049A5 (cg-RX-API-DMAC7.html)
JP2005203960A5 (cg-RX-API-DMAC7.html)
BE2019C535I2 (cg-RX-API-DMAC7.html)
BE2015C033I2 (cg-RX-API-DMAC7.html)